Artiva Biotherapeutics (ARTV) Non Operating Income (2023 - 2026)
Artiva Biotherapeutics (ARTV) posted quarterly Non Operating Income of $914000.0 for Q1 2026, down 50.86% year-over-year from $1.9 million in Q1 2025, and down 21.21% quarter-over-quarter from $1.2 million in Q4 2025.
Artiva Biotherapeutics (ARTV) Non Operating Income (2023 - 2026) Analysis & Trends
Artiva Biotherapeutics (ARTV) has reported Non Operating Income for 4 consecutive years, with $914000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Income fell 50.86% year-over-year to $914000.0; the TTM figure through Mar 2026 stood at $5.0 million (up 54.19% YoY), while the FY2025 annual figure was $5.9 million, up 211.42% from the prior year.
- Non Operating Income retreated to $914000.0 in Q1 2026 per ARTV's latest filing, from $1.2 million in the prior quarter.
- Across five years, Non Operating Income topped out at $2.2 million in Q4 2024 and bottomed at -$1.7 million in Q2 2024.
- Historically, Non Operating Income has averaged $818500.0 across 4 years, with a median of $888500.0 in 2024.
- On a YoY basis, Non Operating Income climbed as much as 4836.36% in 2024 and fell as far as 406.11% in 2024.
- Artiva Biotherapeutics' Non Operating Income stood at $44000.0 in 2023, then surged by 4836.36% to $2.2 million in 2024, then tumbled by 46.59% to $1.2 million in 2025, then dropped by 21.21% to $914000.0 in 2026.
- Business Quant data shows ARTV's Non Operating Income at $914000.0 in Q1 2026, $1.2 million in Q4 2025, and $1.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Artiva Biotherapeutics | 451.28 Mn | 451.28 Mn | - | 1.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.89 Mn |
| Mar 31, 2026 | 914,000.00 |
| Dec 31, 2025 | 1.16 Mn |
| Sep 30, 2025 | 1.37 Mn |
| Jun 30, 2025 | 1.56 Mn |
| Mar 31, 2025 | 1.86 Mn |
| Dec 31, 2024 | 2.17 Mn |
| Sep 30, 2024 | 863,000.00 |
| Jun 30, 2024 | -1.65 Mn |
| Mar 31, 2024 | 529,000.00 |
| Dec 31, 2023 | 44,000.00 |
| Sep 30, 2023 | 468,000.00 |
| Jun 30, 2023 | 540,000.00 |